Last Updated on September 25, 2020 by The Health Master
Zydus Cadila has received final approval from the USFDA to market dimethyl fumarate delayed-release capsules, (US RLD: Tecfidera) in the strengths of 120 mg and 240 mg.
In its approval, the USFDA noted that Zydus was one of the first ANDA applicants to submit a substantially complete ANDA and is, therefore, eligible for 180 days of generic drug exclusivity along with other first ANDA applicants.
The USFDA granted approval following the entry of judgment in favour of Zydus Cadila and other ANDA applicants by the United States District Court for the District of Delaware, holding that the only unexpired patent covering Tecfidera is invalid.
Dimethyl fumarate delayed-release capsules are indicated for the treatment of patients with relapsing forms of multiple sclerosis. These tablets by Zydus Cadila will be manufactured at the group’s manufacturing facility at the SEZ, Matoda.
The group now has 303 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Cipla announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Dimethyl Fumarate DR Capsules 120mg, 240mg and 120mg/240mg Starter Pack from the United States Food and Drug Administration (US FDA).
Cipla’s Dimethyl Fumarate DR Caps 120mg, 240mg and 120mg/240mg Starter Pak is AB-rated generic therapeutic equivalent version of Biogen IDEC Inc’s Tecfidera. It is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
According to IQVIA (IMS Health), Tecfidera had US sales of approximately $3.8 Billion for the 12-month period ending July 2020.